MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

MOLECULAR MEDICINE, published by SPRINGER, is a leading scholarly journal dedicated to advancing the fields of genetics and molecular biology with a focus on clinical applications. Since its inception in 1994, it has evolved to become a pivotal platform for disseminating innovative research findings, achieving a remarkable Q1 ranking in multiple categories, including Genetics, Molecular Biology, and Molecular Medicine as of 2023. Featuring an Open Access model since 2000, the journal ensures that cutting-edge research is freely available to the global scientific community, facilitating collaboration and knowledge exchange. With a commitment to high-quality peer-reviewed content, MOLECULAR MEDICINE serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of molecular research and its implications for medical science. For those interested in contributing to or accessing vital research in this dynamic field, MOLECULAR MEDICINE stands out as a premier choice.

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Welcome to Critical Reviews in Biochemistry and Molecular Biology, a premier academic journal published by Taylor & Francis Ltd, dedicated to advancing the fields of biochemistry and molecular biology. With an impressive impact factor and a Q1 ranking in both Biochemistry and Molecular Biology for 2023, this journal serves as a vital resource for researchers, professionals, and students eager to engage with cutting-edge reviews and analyses that synthesize the latest developments in these dynamic areas of study. Since its inception in 1972, the journal has maintained a commitment to high-quality scholarship, providing a platform for critical discussions that accelerate the discovery and understanding of biochemical processes and molecular interactions. Although not open access, its robust editorial peer-review process ensures that published articles meet the highest standards of scientific rigor, making it a trusted source for the scientific community. As we continue to converge toward 2024, we invite you to explore the extensive array of topics and findings that have shaped contemporary biochemistry and molecular biology.

Molecular Biology Research Communications is a distinguished academic journal published by Shiraz University, focusing on the critical and rapidly evolving fields of biochemistry and molecular biology. With an ISSN of 2322-181X and an E-ISSN of 2345-2005, this journal serves as an essential platform for researchers, professionals, and students to disseminate significant findings that contribute to the advancement of knowledge in these disciplines. The journal, operating from Shiraz, Iran, is notable for its contributions from both local and international scholars, offering invaluable insights and fostering scientific collaboration. Although currently indexed in the Q4 quartile across its categories, the journal aims to enhance its impact and visibility in the field as it converges years of research from 2017 to 2024. While the open access option is not available, the journal's commitment to high-quality peer-reviewed research provides a respected avenue for publication.

INTERNATIONAL JOURNAL OF HUMAN GENETICS is a distinguished publication dedicated to advancing knowledge in the fields of genetics and molecular biology. Published by KAMLA-RAJ ENTERPRISES, this journal explores critical developments and research findings from 2008 to 2016, though its coverage in Scopus has since been discontinued. With an ISSN of 0972-3757 and an E-ISSN of 2456-6330, the journal aimed to foster scholarly dialogue and serve as a resource for researchers, professionals, and students engaged in human genetics. While the journal holds a modest ranking in categories such as Biochemistry and Genetics, it remains a vital source for exploring niche topics within the realm of human genetics. Researchers interested in genetic screening, gene therapy, and clinical genetics will find valuable insights herein. Despite its pause in indexing, the journal continues to contribute to the academic discourse by disseminating critical research that bridges gaps in understanding human genetics.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS is a well-regarded academic journal that serves as a vital platform for researchers in the fields of biochemistry and biophysics. Published by the NATL INST SCIENCE COMMUNICATION-NISCAIR since its inception in 1972, this Open Access journal has committed itself to disseminating high-quality research and advancements in these dynamic fields, allowing readers worldwide to access vital findings since 2009. The journal maintains a robust presence in the academic landscape, achieving noteworthy rankings in 2023, placing it in the Q4 category for Biochemistry and Q3 for both Biophysics and miscellaneous Medicine, alongside its respectable Scopus rankings. With an emphasis on original research articles, reviews, and educational contributions, the INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS plays an essential role in fostering scientific dialogue and collaboration among professionals and students alike. For scholars seeking to stay at the forefront of biochemistry and biophysics research, this journal is an indispensable resource that fosters knowledge exchange and elevates the field on both a national and international scale.

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, published by Elsevier, serves as a pivotal journal in the fields of biochemistry and biophysics, with a long-standing history dating back to 1956. This esteemed publication, bearing the ISSN 0304-4165 and E-ISSN 1872-8006, continuously contributes to advancing our understanding of complex biological processes through rigorous research articles and reviews. It notably holds a distinguished position with a Q2 classification in Biochemistry and a Q1 ranking in Biophysics for 2023, reflecting its high relevance and impact within these scientific domains. The journal is also recognized within the Scopus metrics, taking a rank of #40 out of 152 in Biophysics and #173 out of 438 in Biochemistry, thus placing it in the 74th and 60th percentiles respectively. Academics and professionals in the life sciences will find this journal an essential resource for current research, cutting-edge techniques, and comprehensive reviews aimed at enhancing the understanding of biological functions. While BIOCHIMICA ET BIOPHYSICA ACTA is not an open-access journal, it remains a cornerstone publication for those seeking to stay at the forefront of biochemical and biophysical research.